Launched in 2008, Disease Models & Mechanisms is an Open Access biomedical research journal that advances understanding of the mechanism, diagnosis and therapy of human disease.

Interdisciplinary in scope, Disease Models & Mechanisms covers a diverse range of diseases, including cancer, infectious diseases, developmental disorders, musculoskeletal disorders, and neurodegenerative and neurological diseases. Published research utilizes in vitro or ex vivo models, such as stem-cell-based models, organoids, patient material, model organisms, microorganisms, viruses and computational approaches.

In addition to research articles, Disease Models & Mechanisms features expert reviews, perspectives and interviews with leading scientists to address current and emerging themes in biomedical science.

Readership
Disease Models & Mechanisms aspires to connect and support all those working at every level of disease research, from basic researchers to clinicians at the forefront of patient care. Content is freely available to the journal’s communities of basic and clinical researchers, those working for pharmaceutical companies, health professionals, patients and their advocates and families.

Abstracting and indexing services
Disease Models & Mechanisms is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline, Scopus and the Directory of Open Access Journals (DOAJ).

Open Access commitment
The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are also included in our Read & Publish Open Access agreements.

Key metrics
- 2021 Impact Factor: 5.732
- Five-year Impact Factor: 6.581
- Two-year citation median: 4.0
- Eigenfactor score: 0.01083
- Article Influence Score: 1.684
- Immediacy Index: 1.262
- h-index: 93
- Scopus CiteScore: 9.0
- SJR indicator: 1.874
- SNIP: 1.211

biologists.com/read-publish
Available through The Company of Biologists’ Read & Publish Open Access initiative

What are the benefits of Read & Publish agreements?

- Unlimited “read” access to our three subscription journals – Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S

“The Read & Publish agreement initiative is a great advance enabling open access to research. The agreement between The Company of Biologists and my university made it simple to publish Open Access quickly and fee-free; a great incentive to publish in their suite of journals.”

Dr Katharine Irvine, The University of Queensland, Australia

Benefits of Open Access publishing

- Usage increase >3x
- Citation advantage 1.1–1.4x
- Altmetrics boost 1.2–1.9x

Read & Publish: number of participating institutions

<table>
<thead>
<tr>
<th>Month</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>10</td>
<td>48</td>
<td>415</td>
<td>602</td>
</tr>
</tbody>
</table>

Figures based on the latest available data from Impact Vizor and Altmetric Explorer

biologists.com/read-publish